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RESULTS: A total of six systematic reviews (SR) were found and met our inclusion 
criteria. For the indolent indication: a) Wake et al. 2002 and Schulz et al. 2007 evalu-
ated the treatment as ﬁrst line or subsequent therapies; b) Vidal et al. 2009 and Aksoy 
et al. 2009 assessed the maintenance therapy; c) Cheung et al. 2007 evaluated: ﬁrst 
line and subsequent therapies, maintenance and aggressive NHL; and d) Knight et al. 
2004 evaluated aggressive NHL. Only three studies developed a meta-analysis (Vidal, 
Schulz and Aksoy). According to the SRs rituximab induced remission, improved 
overall survival and disease control. Twenty ﬁve HTAR were found: 5 indicated the 
analysis through inexistent links; 2 belonged to sites with content blocked to non-
members; 2 related to other drugs; 3 indicated ongoing analysis; 3 related to other 
indications. Consequently, 10 reports met the survey criteria. Seven out of 10 pub-
lished HTAR support the use of rituximab for indolent or aggressive lymphomas. 
There are three assessments which are not conclusive. CONCLUSIONS: Findings from 
systematic reviews suggest that rituximab offer better clinical outcomes to patients. 
Most of the Health Technology Assessment reports indicate rituximab as a cost-
 effective alternative.
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OBJECTIVES: The use of Trastuzumab (T) for the adjuvant treatment of breast cancer 
patients (BCP) has been tested in clinical trials. Our goal is to perform a health tech-
nology evaluation in order to stablish if the scientiﬁc evidences are strong enough to 
support the use of T and to compare its cost-effectiveness ratio (CER) with other 
treatments covered by the public sector in Brazil. METHODS: We performed a litera-
ture search, looking for randomized controlled clinical trials (RCTs), systematic 
reviews (SR), guidelines, pharmacoeconomic analysis and endorsements from regula-
tory agencies on the use of T for BCP. RESULTS: We found ﬁve RCTs, three SR, six 
guidelines / health technology assessments and three endorsements from regulatory 
agencies. Four RCTs tested Trastuzumab 2 mg/kg/week or 6 mg/kg/ every 3 weeks 
during one year, in patients with tumors  1 cm. All of these showed a 50% reduction 
on risk of relapse and a 40% reduction in death risk. SR conﬁrmed these ﬁndings. 
The only study that did not show a survival gain, used T for only nine weeks. Guide-
lines and regulatory agencies recomend the use of T for one year. On the pharmaco-
economic perspective, T has a CER similar or better than other procedures covered 
by the public sector in Brazil, such as heart transplant, tacrolimus for kidney trans-
plantation, ribavirin plus peg-interferon for C hepatitis and bone marrow transplant. 
These procedures have a CER betwen US$35,000 and US$45,000 / QALY (or above). 
The CER of adjuvant T is around US$20,000/QALY. CONCLUSIONS: Trastuzumab 
is indicated for the adjuvant treatment of BCP, and must be considered as standard 
treatment for these patients. Also, from a pharmacoeconomic point of view, it’s CER 
is similiar to other medical interventions covered by the Brazilian health care public 
system.
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REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT 
AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF 
COLORECTAL CANCER
Saggia MG, Borges LG
Roche Brazil, Sao Paulo, SP, Brazil
OBJECTIVES: To conduct a review of the Health Technology Assessments (HTA) 
recommendations published on the International Network of HTA (INAHTA) website 
concerning the use of capecitabine to treat colorectal cancer in order to support the 
decision making in Brazil. METHODS: A search was conducted on INAHTA website 
(www.inahta.org), in English language, for the key word “capecitabine”. Nineteen 
results were found, from which: 5 referred to other drugs; 6 to other capecitabine 
indication; 1 indicated an ongoing analysis, consequently, 7 results met our objective. 
RESULTS: The economic assessments found were conducted in Europe (6) and Argen-
tina (1). All reports positively recommended the use of capecitabine. In the metastatic 
setting, the assessment made in 2003 by the NHS of Scotland and NICE (England) 
recommended capecitabine as an option for ﬁrst line monotherapy; that of the NIHR 
Health Technology Assessment programme (England, 2003) showed that there are 
cost savings associated with the use of capecitabine and that of the IECS (Argentina, 
2004), concluded that capecitabine could be a therapeutic option with an easier 
administration and better safety proﬁle. In the adjuvant setting, the NHSC (England, 
2003) assessed that capecitabine may have a signiﬁcant beneﬁcial impact on patients, 
health services and staff. In 2006, NICE recommended capecitabine as monotherapy 
for patients with stage III (Dukes’ C) colon cancer following surgery and the NIHR 
Health Technology Assessment programme showed that capecitabine is cost-effective 
in comparison with 5-FU/LV regimens. The authors also suggested that further 
research is necessary to compare effectiveness of capecitabine with other 5-FU/LV 
infusion regimens common used. CONCLUSIONS: According to this review, all 
published economic assessments up to the present date support the use of capecitabine 
for colorectal cancer (metastatic and adjuvant therapy).
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OBJECTIVES: To conduct a review of Health Technology Assessments (HTA) recom-
mendations published on the International Network of HTA (INAHTA) website 
concerning use of capecitabine to treat breast cancer in order to support decision 
making in Brazil. METHODS: A search was conducted on INAHTA website (www.
inahta.org), in English language, for the key word “capecitabine”. Nineteen results 
were found, from which: 5 referred to other drugs; 10 to other capecitabine indica-
tions; consequently, 4 results met our objective. RESULTS: The economic assessments 
found were conducted in Europe (3) and Argentina (1). From these, 3 positively recom-
mend the use of capecitabine for breast cancer and 1 did not state a clear recommenda-
tion, though considering that capecitabine seems to be a cost-effective therapy. The 
analysis conducted in 2003 by the NHS of Scotland for metastatic breast cancer, 
and that of the NICE (England) for locally advanced or metastatic breast cancer were 
replaced by NICE guidance CG81 (2009), which recommended capecitabine as mono-
therapy for second or third line in patients for whom anthracycline-containing 
regimens are unsuitable or have failed. In 2004, the IECS(Argentina), concluded 
that capecitabine can be a therapeutic option for locally advanced or metastatic 
breast cancer combined with docetaxel or as monotherapy. The assessment stated 
that capecitabine should be used when patients failed or are not eligible for anthracy-
cline-containing regimens. The assessment by NIHR Health Technology Assessment 
programme (England, 2004), indicated that capecitabine treatment as monotherapy 
or combined with docetaxel for locally advanced and/or metastatic breast cancer 
appears to be cost-effective. However, the authors stated that the evidence base 
for assessment was poor and further investigation is necessary. CONCLUSIONS: 
According to this review, the published economic assessments up to the present 
date suggest capecitabine as an option for the treatment of breast cancer (locally 
advanced or metastatic) for patients who failed or are not eligible for anthracycline-
containing regimens.
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PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN  
FRENCH HOSPITALS
Degrassat-Théas A1, Bensadon M2, Rieu C1, Le Pen C3, Paubel P1
1Sainte-Anne Hospital, Paris, France, 2Agence Technique de l’Information sur l’Hospitalisation, 
Lyon, France, 3Dauphine University, Paris, France
OBJECTIVES: Since 2004, hospital cares are ﬁnanced by allotted amounts at a 
speciﬁc diagnosis-based level. In order to guarantee access to innovative drugs, high-
cost drugs are gathered on a positive list and are paid out of the budget with a total 
reimbursement under conditions of good use. As hospital drugs prices are free, the 
regulator sets up a reimbursement price cap in 2005, named responsibility tariff (RT), 
to avoid uncontrolled increase of prices due to a low interest in negotiation between 
hospitals and ﬁrms. The aim of this work is to assess the impact of this regulation 
measure on cancer drugs market between 2004 and 2007. METHODS: This study 
uses data from the technical agency of information on hospitals and included establish-
ments previously under ﬁxed global budget. Those data, from 2004 to 2007, provide 
quantities, expenditures and purchase prices of cancer drugs on this list belonging to 
the L01 level of the world health organization anatomical therapeutic and chemical 
classiﬁcation. Furthermore, an index representing the ratio of the purchase prices 
and the RT is built. RESULTS: The consumption of L01 drugs shows an important 
evolution with a 17.2% yearly growth rate between 2005 and 2007. Expenditures 
exceed 1.6 billions of euros in 2007. The contribution of L01 in spending of the high-
cost drugs list reaches 66% in 2006 and 37% in 2007. The RT leads to a transient 
prices decrease in 2005 before an alignment on regulated prices. Only competitive 
market allows low prices under RT. CONCLUSIONS: The rising spending of cancer 
drugs is due to the consumption of recent and expensive drugs. Their rationalization 
implies a strict innovation evaluation. The optimal level of innovation still needs to 
be deﬁned.
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OBJECTIVES: Due to wide variations in prescribing practice, a key methodological 
challenge for an economic analysis in oncology is describing current practice. Robust 
methods of eliciting the full range of expert opinion are necessary to ensure clinical 
relevance and validity of economic models. Insufﬁcient information about variations 
in management can lead to model underestimation of uncertainty. This study aims to 
determine the appropriate model structure for an economic evaluation of a pharma-
cogenetic test to inform irinotecan prescribing, by identifying current practice. 
METHODS: Expert opinion was elicited to inform model structure. Through semi-
structured postal survey (May-August 2008), clinical experts were asked to describe: 
the general management of advanced CRC patients on chemotherapy, place of irino-
tecan-based regimens within the clinical pathway and management of patients on these 
regimens. Since data on the frequency of key adverse events (neutropaenia and 
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diarrhoea) from irinotecan-based regimens are not readily available, experts were 
asked to provide frequency estimates and resources associated with management. 
Descriptive statistics were used to summarise the data. RESULTS: The ﬁnal expert 
panel comprised 44 oncologists representing all English NHS regions, from a sample 
of 98 potential experts. Wide variations in prescribing practice were identiﬁed. There 
were ten ﬁrst-line, ten second-line and twelve third-line chemotherapy regimens 
reported, reﬂecting variation in practice. However, dominant treatment pathways 
emerged for each stage of treatment, with: ﬁrst-line treatment with oxaliplatin-based 
regimens, second-line treatment with irinotecan-based regimens, and third-line treat-
ment with mitomycin-based regimens. Experts estimated the frequency of: febrile 
neutropaenia 8.4% (95% CI: 6.7–10.0), septic neutropaenia 4.7% (95% CI: 3.4–6.0), 
and severe diarrhoea 13.1% (95% CI: 10.8–15.5). CONCLUSIONS: This study 
captured the heterogeneity in chemotherapy prescribing practice and patient manage-
ment within CRC specialties and obtained necessary data to inform the appropriate 
model structure for base case and subsequent structural and parameter sensitivity 
analyses.
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TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST 
CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A 
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OBJECTIVES: Current treatment practices for patients in Australia with advanced 
breast cancer (ABC) who have previously been treated with an anthracycline and a 
taxane (A&T) are not well deﬁned. There is no “gold standard” treatment for these 
heavily pre-treated patients. A retrospective longitudinal survey was conducted to gain 
an insight into the treatments currently used in this patient group. METHODS: Four 
public hospitals provided patient level data. Inclusion criteria encompassed women 
q18 years with ABC who had previously received A&T therapy and had q3 months 
follow-up. Information on demographics, disease characteristics and treatment history 
was obtained from medical records of all eligible patients. Descriptive statistics were 
performed by disease characteristics and treatments prescribed by line of therapy post 
A&T. RESULTS: Data were obtained from 79 patient records. The mean (SD) age at 
initial diagnosis was 51.5 (10.9) years with most patients having stage IIIA disease 
(45.6%). Seventy four patients (93.7%) had previously undergone surgery. The most 
common ﬁrst-line therapies post A&T were monotherapy or combination use of 
radiotherapy (39/79, 49.4%), cytotoxic chemotherapy (36/79, 45.6%), targeted 
therapy (11/79, 13.9%) and hormonal therapy (8/79, 10.3%). Paclitaxel, whether 
used alone or in combination, was the most common ﬁrst-line cytotoxic treatment 
post A&T (11/79, 13.9%), followed by cyclophosphamide (10/79, 12.7%), doxoru-
bicin (9/79, 11.4%) and docetaxel (7/79, 8.9%). Cytotoxic mono-chemotherapies 
were more commonly prescribed ﬁrst-line post A&T than cytotoxic combination 
treatments (31.6% vs. 13.9%) with paclitaxel (9/79, 11.4%), docetaxel (5/79, 6.3%) 
and capecitabine (4/79, 5.1%) being most frequently prescribed. FEC (4/79, 5.1%) 
and doxorubicin/cyclophosphamide (3/79, 3.8%) were the most commonly adminis-
tered cytotoxic ﬁrst-line combinations. CONCLUSIONS: The considerable variation 
in the treatments prescribed for patients with ABC who have previously received A&T 
highlight the need for an effective treatment option. Radiotherapy and cytotoxic che-
motherapy were the most frequently administered therapies, with paclitaxel being 
most commonly prescribed cytotoxic agent.
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PIH1
PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT 
OF VIEW OF PUERPERAL MOTHERS
Kovács E, Vránics I, Boncz I, Paljunite A, Bódis J, Gabara K, Kriszbacher I
University of Pécs, Pécs, Hungary
OBJECTIVES: Pain, such as pain following Caesarean section is a subjective and 
complex experience, from the intensity of which we can get a forecast with the respect 
of a number of inﬂuencing factors. The aim of this study is to examine those factors 
that inﬂuence postoperative pain after Caesarean section. METHODS: Our examina-
tion was made among women and went through a Caesarean section University of 
Pécs Obstetric and Gynecology Clinic and Hospital of Baranya County between 
October 1, 2008 and December 31, 2008 in Hungary. Our own questionnaire and 
a numerical classiﬁer scale were used to measure the intensity of pain. Under the 
examination time we got back altogether 183 valuable questionnaires from the two 
institutions. Khi2 test, t-test, ANOVA variance analysis, Pearson-Sperman correlation 
coefﬁcient examination was used for the analysis. Data processing was done with SPSS 
15.0 and MS Excel programs. RESULTS: Based on the results of our research a sig-
niﬁcant connection can be shown through the examination of postoperative pain 
following Caesarean section in case of school (p  0.01), the method of anesthesia 
(p  0.002; p  0.041) and the memory of the previous Caesarean section (p  0.03; 
p  0.008). CONCLUSIONS: According to the results of our study those who had 
higher qualiﬁcation had higher postoperative pain intensity and lower functional 
activity than mothers with lower qualiﬁcations. Examining the anesthesia method we 
can say that those mothers who were narcotized reported bigger postoperative pain 
than those mothers who got epidural anesthesia.
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ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE 
SEROTONIN REUPTAKE INHIBITORS (SSRI’S) ANTIDEPRESSANT 
MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE 
EVENT REPORTING SYSTEM (AERS)
Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the adverse events in children treated with SSRIs reported 
through the FDA’s Adverse Event Reporting System in response to the increased risks 
of suicide among children being treated with antidepressants. METHODS: A retro-
spective pharmacovigilance analysis was conducted using the January 2004 to Sep-
tember 2006 FDA Adverse Event Reporting System (AERS) data. The adverse drug 
event cases (ADEs) associated with SSRI antidepressants were identiﬁed based on the 
role of the medication in the incidence of the ADEs as the Primary and Secondary 
suspect. Children were deﬁned as patients below 18 years. RESULTS: Out of 68,936 
ADE cases involving SSRI antidepressants, the SSRIs were identiﬁed as the primary 
suspect in 27,075 cases and as the secondary suspect in 6,713 cases. Of those cases, 
there were merely 1,780 (5.26%) cases involving children. The number of cases 
reported to the FDA per quarter was 161.81 on an average for the 11 quarters data. 
Paroxetine accounted for the majority of the reported ADE, 778 (43.70%) cases 
involving children followed by Sertraline 315 (17.69%) and Escitalopram 273 
(15.33%). Despite the low reporting rate, adverse events associated with SSRI anti-
depressants can have serious consequences. Suicide attempt was reported in 579 cases 
(16.88%) followed by psychotic disorders in 420 cases (12.24%). More than one third 
(608, 38.23%) of those cases led to hospitalization. CONCLUSIONS: Despite that 
the adverse events reported for SSRI antidepressants being taken by children were low; 
the consequences of those adverse events can be very serious. Suicide attempt was the 
most commonly reported adverse event. Paroxetine was the most common SSRI to be 
reported for adverse events and the main outcome was hospitalization.
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DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR 
IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE: 4-YEAR 
RESULTS FROM THE COMBINATION OF AVODART® AND 
TAMSULOSIN (COMBAT) STUDY
Haillot O1, Budia A2, Wilson T3, Black L3
1Universite F. Rabelais, Tours, France, 2La Fe University Hospital, Valencia, Spain, 
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OBJECTIVES: Lower urinary tract symptoms (LUTS) secondary to benign prostatic 
hyperplasia (BPH) represent a signiﬁcant burden in affected men, with increasingly 
severe LUTS associated with a lower quality of life (QoL). 2-year primary analyses of 
the CombAT study (n  4844) showed that dutasteride plus tamsulosin provided sig-
niﬁcantly greater symptom and QoL improvement versus either monotherapy. Here 
we present 4-year data on the effects of dutasteride plus tamsulosin compared with 
each monotherapy on the patient-reported health outcomes, BPH Impact Index (BII) 
and International Prostate Symptom Score (IPSS) Q8. METHODS: Following screen-
ing, eligible subjects entered a single-blind run-in period during which they received 
dutasteride and tamsulosin placebos for four weeks. All subjects were then randomised 
to receive 0.5 mg dutasteride, 0.4 mg tamsulosin or the combination once daily for 4 
years. The primary endpoint for the 4-year analysis was time to acute urinary retention 
or BPH-related surgery; secondary endpoints included change from baseline in IPSS, 
BII and IPSS Q8. RESULTS: At baseline, mean BII and IPSS Q8 were 5.3 and 3.6, 
respectively, in all three treatment groups. Mean change from baseline in BII at Month 
48 was 2.2 with combination therapy, 1.8 with dutasteride and 1.2 with tamsu-
losin (both p  0.001 versus combination). For IPSS Q8, the corresponding values 
were 1.5 with combination, 1.3 with dutasteride and 1.1 with tamsulosin (both p 
 0.001 versus combination). Improvement in BII and IPSS Q8 from baseline with 
combination therapy was statistically greater than with dutasteride from 3 months; 
compared with tamsulosin, the improvement from baseline with combination was 
statistically greater from 9 months (BII) and 12 months (IPSS Q8). CONCLUSIONS: 
Dutasteride combined with tamsulosin delivers superior improvement in health out-
comes (BII and IPSS Q8) versus either monotherapy. The superiority of combination 
therapy over dutasteride was observed from three months, and over tamsulosin as 
early as nine months.
PIH4
ROLE OF LIFESTYLE-RELATED FACTORS IN PELVIC FLOOR MUSCLE 
STRENGTH CHANGES DURING PREGNANCY
Hock M, Kránicz J, Kriszbacher I, Boncz I, Bódis J
University of Pécs, Pécs, Hungary
OBJECTIVES: To assess strength and duration of pelvic ﬂoor muscle (PFM) contrac-
tion and to monitor the changes of lifestyle-related factors (body weight, constipation, 
vaginal wall laxity and physical activity) during pregnancy. METHODS: Our study 
focused on examining the strength and duration of pelvic ﬂoor muscle contraction in 
pregnant women during the 2nd and 3rd trimesters. Parameters were measured by a 
device for measuring vaginal pressure. Statistical data were calculated according 
to mean, standard deviation, T-test methods and the results were considered to be 
relevant at p  0.05. RESULTS: Data of 93 women were analyzed. The maximum 
muscle strength of nulliparous women (n  36) was signiﬁcantly higher (p  0.003) 
than that of pregnant women (n  57). The duration of maximum contraction in case 
of nulliparous women proved to be markedly longer (p  0.011) than during preg-
nancy. Regarding lifestyle factors even when BMI and constipation were involved no 
